#Tico trial trial#

1, 2 Although ticagrelor reduces ischemic events in these patients, bleeding is a major treatment‐related concern. It is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y12 inhibitor therapy in patients with acute coronary syndrome (ACS) treated with dual antiplatelet therapy (DAPT) after coronary stent implantation. These bleeding factors may be considered for adopting ticagrelor as P2Y12 inhibitor therapy among patients with acute coronary syndrome undergoing drug‐eluting stent implantation.

#Tico trial trial#

The lower risk of a net adverse clinical event (a composite of TIMI major bleeding and major adverse cardiac and cerebrovascular events) in patients treated with 3‐month aspirin therapy reported from the TICO trial remained valid in patients with any of these risk factors (hazard ratio, 0.59 95% CI, 0.39–0.90 P interaction=0.74). In contrast, 3‐month aspirin therapy with continued ticagrelor (versus 12‐month aspirin and ticagrelor) was associated with a decreased risk of major bleeding. On the basis of multivariable and receiver operating characteristic curve analyses, weight ≤65 kg, hemoglobin ≤12 g/dL, and estimated glomerular filtration rate <60 mL/min per 1.73 m 2 were associated with an increased risk of major bleeding. Patients with major bleeding, defined by TIMI (Thrombolysis in Myocardial Infarction) major or Bleeding Academic Research Consortium type 3 or 5, were compared with those without major bleeding.

Stroke: Vascular and Interventional Neurologyįrom the TICO (Ticagrelor Monotherapy After 3 Months in Patients Treated With New Generation Sirolimus‐Eluting Stent for Acute Coronary Syndrome) randomized trial, a total of 2660 patients were included for the present study.Journal of the American Heart Association (JAHA).

Circ: Cardiovascular Quality & Outcomes.

Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).